Abstract
Alzheimers disease (AD) is a neurodegenerative disorder histologically defined by the cerebral accumulation of amyloid deposits and neurofibrillary tangles composed of hyperphosphorylated tau proteins. Loss of basal forebrain cholinergic neurons is another hallmark of the disease thought to contribute to the cognitive dysfunctions. To this date, the mechanisms underlying cholinergic neurons degeneration remain uncertain. The present study aimed to investigate the relationship between neurofibrillary degeneration and cholinergic defects in AD using THY-Tau22 transgenic mouse model exhibiting a major hippocampal AD-like tau pathology and hyperphosphorylated tau species in the septohippocampal pathway. Here, we report that at a time THY-Tau22 mice display strong reference memory alterations, the retrograde transport of fluorogold through the septohippocampal pathway is altered. This impairment is associated with a significant reduction in the number of choline acetyltransferase (ChAT)-immunopositive cholinergic neurons in the medial septum. Analysis of nerve growth factor (NGF) levels supports an accumulation of the mature neurotrophin in the hippocampus of THY-Tau22 mice, consistent with a decrease of its uptake or retrograde transport by cholinergic terminals. Finally, our data strongly support that tau pathology could be instrumental in the cholinergic neuronal loss observed in AD.
Keywords: Alzheimer's disease, Cholinergic neurons, Nerve growth factor, Tau, Transgenic model, cognitive impairments, dementia, neurofibrillary tangles, sequential cleavage, neurotrophins, discrepancies, forebrain cholinergic neurons, cognitive dysfunction, P75NTR receptor
Current Alzheimer Research
Title: Loss of Medial Septum Cholinergic Neurons in THY-Tau22 Mouse Model: What Links with tau Pathology?
Volume: 8 Issue: 6
Author(s): K. Belarbi, S. Burnouf, F.-J. Fernandez-Gomez, J. Desmercieres, L. Troquier, J. Brouillette, L. Tsambou, M.-E. Grosjean, R. Caillierez, D. Demeyer, M. Hamdane, K. Schindowski, D. Blum and L. Buee
Affiliation:
Keywords: Alzheimer's disease, Cholinergic neurons, Nerve growth factor, Tau, Transgenic model, cognitive impairments, dementia, neurofibrillary tangles, sequential cleavage, neurotrophins, discrepancies, forebrain cholinergic neurons, cognitive dysfunction, P75NTR receptor
Abstract: Alzheimers disease (AD) is a neurodegenerative disorder histologically defined by the cerebral accumulation of amyloid deposits and neurofibrillary tangles composed of hyperphosphorylated tau proteins. Loss of basal forebrain cholinergic neurons is another hallmark of the disease thought to contribute to the cognitive dysfunctions. To this date, the mechanisms underlying cholinergic neurons degeneration remain uncertain. The present study aimed to investigate the relationship between neurofibrillary degeneration and cholinergic defects in AD using THY-Tau22 transgenic mouse model exhibiting a major hippocampal AD-like tau pathology and hyperphosphorylated tau species in the septohippocampal pathway. Here, we report that at a time THY-Tau22 mice display strong reference memory alterations, the retrograde transport of fluorogold through the septohippocampal pathway is altered. This impairment is associated with a significant reduction in the number of choline acetyltransferase (ChAT)-immunopositive cholinergic neurons in the medial septum. Analysis of nerve growth factor (NGF) levels supports an accumulation of the mature neurotrophin in the hippocampus of THY-Tau22 mice, consistent with a decrease of its uptake or retrograde transport by cholinergic terminals. Finally, our data strongly support that tau pathology could be instrumental in the cholinergic neuronal loss observed in AD.
Export Options
About this article
Cite this article as:
Belarbi K., Burnouf S., Fernandez-Gomez F.-J., Desmercieres J., Troquier L., Brouillette J., Tsambou L., Grosjean M.-E., Caillierez R., Demeyer D., Hamdane M., Schindowski K., Blum D. and Buee L., Loss of Medial Septum Cholinergic Neurons in THY-Tau22 Mouse Model: What Links with tau Pathology?, Current Alzheimer Research 2011; 8 (6) . https://dx.doi.org/10.2174/156720511796717230
DOI https://dx.doi.org/10.2174/156720511796717230 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cells as a Potential Therapeutic Option for Treating Neurodegenerative Diseases
Current Stem Cell Research & Therapy The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells
Current Medicinal Chemistry The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease
Current Topics in Medicinal Chemistry Molecular Profiling - An Essential Technology Enabling Personalized Medicine in Breast Cancer
Current Drug Targets Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology Small Molecule Fluorescent Ligands as Central Nervous System Imaging Probes
Mini-Reviews in Medicinal Chemistry GSK-3 Inhibitors: Discoveries and Developments
Current Medicinal Chemistry BCL-2 Family Proteins: The Mitochondrial Apoptotic Key Regulators
Current Cancer Therapy Reviews Human Embryonic Stem Cell Therapies for Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Harvesting New Therapeutic Avenues with Stem Cell Applications
Current Neurovascular Research Fluorinated Molecules as Drugs and Imaging Agents in the CNS
Current Topics in Medicinal Chemistry Targeting Stress Activated Protein Kinases, JNK and p38, as New Therapeutic Approach for Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry The Effects of Variants in the Parkin, PINK1, and DJ-1 Genes along with Evidence for their Pathogenicity
Current Protein & Peptide Science Creatine and the Liver: Metabolism and Possible Interactions
Mini-Reviews in Medicinal Chemistry The Neuroinflammatory Response in Plaques and Amyloid Angiopathy in Alzheimers Disease: Therapeutic Implications
Current Drug Targets - CNS & Neurological Disorders Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery Isoflurane Facilitates Synaptic NMDA Receptor Endocytosis in Mice Primary Neurons
Current Molecular Medicine Transgenic C. elegans as a Model in Alzheimers Research
Current Alzheimer Research